trending Market Intelligence /marketintelligence/en/news-insights/trending/88qGnA6vHU5MfUqOWRBV5A2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

CSL's autoimmune drug granted US FDA's orphan drug designation

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


CSL's autoimmune drug granted US FDA's orphan drug designation

CSL Ltd.'s autoimmune disorder medicine has been granted orphan drug designation by the U.S. Food and Drug Administration.

The regulator's decision on CSL's Hizentra provides for a seven-year period of marketing exclusivity in the U.S. as a maintenance therapy to prevent the return of chronic inflammatory demyelinating polyneuropathy in certain adult patients. The disorder targets the peripheral nerves and may cause permanent nerve damage.

The FDA grants the designation for medications that treat rare diseases affecting fewer than 200,000 patients in the U.S.

Hizentra is already approved in Japan and the U.S. to prevent relapse of chronic inflammatory demyelinating polyneuropathy in adults. Additionally, the drug is approved in over 50 countries to treat certain immune deficiencies.